Skip to main content

Moxham Christopher's Form 4 filing

Fulcrum Therapeutics, Inc. (FULC) · filed Aug 12, 2021

Accession no.
0000899243-21-032755
Filed
Aug 12, 2021
Trade date
Aug 10, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $911.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Moxham ChristopherCIK 0001843784Officer (Chief Scientific Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 10, 2021Common StockMOption exerciseAcquired+20,714$7.84+$162,397.7620,714Direct
Aug 10, 2021Common StockSSaleDisposed−20,714$17.00−$352,1380Direct
Aug 10, 2021Common StockMOption exerciseAcquired+31,071$7.84+$243,596.6431,071Direct
Aug 10, 2021Common StockmSSaleDisposed−31,071$18.00−$559,2780Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 10, 2021Common StockMOption exerciseDisposed−20,714$0.00$0103,572Direct
Aug 10, 2021Common StockMOption exerciseDisposed−31,071$0.00$072,501Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)